BioSyent Announces Introduction of New FeraMAX® Pd
October 05 2020 - 7:00AM
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is
pleased to announce the introduction of FeraMAX® Pd, a new oral
iron supplement formulation, by its subsidiary BioSyent Pharma Inc.
FeraMAX® Pd is a patented delivery system for the treatment of iron
deficiency anemia and will be the foundation of future product
developments.
BioSyent Pharma has a deep expertise and
experience in the iron deficiency anemia therapy and prevention
market, and in collaboration with its manufacturing partner, has
developed a new proprietary formulation that will serve the needs
of patients that suffer from low blood iron levels.
“We are excited about this new patented FeraMAX®
Pd formulation which forms the platform for future product
innovation,” commented René Goehrum, President and CEO of BioSyent
Inc. “This introduction furthers BioSyent’s commitment to iron
deficiency management and enables us to better meet the needs of
healthcare professionals and patients through continued investment
in the brand. Later this year we’ll be sharing news of the first
product to use this new iron delivery system.”
FeraMAX® Pd is made with a homogeneous
polysaccharide, Polydextrose, linked to ferric (Fe3+) elemental
iron to form the proprietary iron complex, Polydextrose Iron
Complex (“PDIC”). This formulation differs from the current
FeraMAX® formulation which uses a heterogeneous mixture of
polysaccharides in the iron complex forming a Polysaccharide Iron
Complex (“PIC”). The change in formulation of FeraMAX® provides a
more uniform molecular structure.
FeraMAX® Pd’s new enhanced delivery system,
combined with its confirmed efficacy and good tolerability, make it
the ideal choice for iron deficient patients who cannot tolerate
ferrous salt-based oral iron alternatives.
Canadian healthcare providers and patients can
confidently rely on the new formulation to provide the same
benefits that have made FeraMAX® the #1 recommended iron supplement
by Canadian Pharmacists and Physicians for five consecutive years,
including 2020 (Pharmacy Practice+ and Profession Santé 2020 / The
Medical Post and Profession Santé 2020 – Survey on OTC Counselling
and Recommendations).
FeraMAX® Pd is Vegan Certified and is recognized
by the Society of Obstetricians and Gynaecologists of Canada.
About BioSyent Inc.
Listed on the TSX Venture Exchange under the
trading symbol “RX”, BioSyent is a profitable growth-oriented
specialty pharmaceutical company focused on in-licensing or
acquiring innovative pharmaceutical and other healthcare products
that have been successfully developed, are safe and effective, and
have a proven track record of improving the lives of patients.
BioSyent supports the healthcare professionals that treat these
patients by marketing its products through its community,
specialty/hospital, and international business units.
As of the date of this press release, the
Company has 12,808,600 common shares outstanding.
For a direct market quote for the TSX Venture
Exchange and other Company financial information please visit
www.tmxmoney.com.
For further information please
contact:
Mr. René C. GoehrumPresident and CEOBioSyent
Inc.E-Mail: investors@biosyent.comPhone: 905-206-0013Web:
www.biosyent.com
This press release may contain information or
statements that are forward-looking. The contents herein
represent our judgment, as at the release date, and are subject to
risks and uncertainties that may cause actual results or outcomes
to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited
to, those associated with clinical trials, product development,
future revenue, operations, profitability and obtaining regulatory
approvals.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this press release.
Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024